Abstract
Humans with a missense mutation in LRP5 (encoding lipoprotein receptor-related protein 5) have a high bone mass phenotype, which has now been recapitulated in mice conditionally expressing this Lrp5 variant in terminally differentiated bone osteocytes (pages 684–691). These results suggest that LRP5 acts locally to increase bone mass, thereby opening avenues for new therapeutics for osteoporosis and bone injury by manipulating LRP5 signaling.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
